Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics

Executive Summary

Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.

You may also be interested in...



Battleground GLP-1s: After Chinese Firms, Glenmark Debuts Liraglutide; More Coming

After China, India sees the arrival of a biosimilar to Novo Nordisk’s Victoza at a sharp discount, while action also appears to be heating up for the Danish firm's high-flying GLP-1, semaglutide, in both markets.

Battleground GLP-1s: After Chinese Firms, Glenmark Debuts Liraglutide; More Coming

After China, India sees the arrival of a biosimilar to Novo Nordisk’s Victoza at a sharp discount, while action also appears to be heating up for the Danish firm's high-flying GLP-1, semaglutide, in both markets.

AbbVie Looks To Umoja To Partner On In Vivo CAR-Ts

Umoja’s technology is meant to enable development of CAR-Ts that could potentially overcome the challenges associated with autologous cell therapies, especially related to manufacturing.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel